{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:06:07Z","timestamp":1790723167845,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024QH052"],"award-info":[{"award-number":["ZR2024QH052"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.cca.2026.121134","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:41:01Z","timestamp":1780616461000},"page":"121134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinicopathological response and survival outcomes of HER2-low versus HER2-zero early breast Cancer: A systematic review and Meta-analysis"],"prefix":"10.1016","volume":"592","author":[{"given":"Lijuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minpu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2026.121134_bb0005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.semcancer.2025.10.006","article-title":"Microbial modulation as a game changer: boosting immunotherapy efficacy in breast cancer","volume":"117","author":"Xia","year":"2025","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.cca.2026.121134_bb0010","article-title":"Deregulated MicroRNAs involved in P53 Signaling pathway in breast Cancer with focus on triple-negative breast Cancer","volume":"17","author":"Naeimzadeh","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.cca.2026.121134_bb0015","doi-asserted-by":"crossref","DOI":"10.2174\/0118761429263063231204095516","article-title":"Anticancer properties of baicalin against breast Cancer and other Gynecological cancers: therapeutic opportunities based on underlying mechanisms","volume":"17","author":"Pourhanifeh","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.cca.2026.121134_bb0020","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cca.2026.121134_bb0025","article-title":"Ingenious designed a HER2-specific macrophage biomimetic multifunctional nanoplatform for enhanced bio-photothermal synergistic therapy in HER2 positive breast cancer","volume":"26","author":"Yang","year":"2024","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.cca.2026.121134_bb0030","article-title":"An artificial signaling pathway primitive-based intelligent biomimetic nanoenzymes carrier platform for precise treatment of Her2 (+) tumors","volume":"26","author":"Sun","year":"2024","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.cca.2026.121134_bb0035","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.32604\/or.2025.065394","article-title":"Investigation on the anti-Cancer effects of HER2-targeted CAR-T cells engineered using the PiggyBac transposon system","volume":"33","author":"Li","year":"2025","journal-title":"Oncol. Res."},{"key":"10.1016\/j.cca.2026.121134_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102064","article-title":"Biomarkers for HER2-positive metastatic breast cancer: beyond hormone receptors","volume":"88","author":"Dieci","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cca.2026.121134_bb0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","article-title":"Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond","volume":"72","author":"Marchi\u00f2","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.cca.2026.121134_bb0050","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.32604\/or.2025.065029","article-title":"Disitamab Vedotin in HER2-positive and HER2-low breast Cancer: a Multicenter retrospective analysis","volume":"33","author":"Zhang","year":"2025","journal-title":"Oncol. Res."},{"key":"10.1016\/j.cca.2026.121134_bb0055","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cca.2026.121134_bb0060","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.3390\/cancers13112824","article-title":"HER2-low breast Cancer: molecular characteristics and prognosis","volume":"13","author":"Agostinetto","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cca.2026.121134_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"22","key":"10.1016\/j.cca.2026.121134_bb0070","article-title":"Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean breast Cancer society","volume":"24","author":"Won","year":"2022","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.cca.2026.121134_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101592","article-title":"Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis","volume":"8","author":"Molinelli","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.cca.2026.121134_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216763","article-title":"Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-low breast Cancer","volume":"588","author":"Han","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cca.2026.121134_bb0085","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-19-1004","article-title":"ARX788, a site-specific anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers","volume":"19","author":"Skidmore","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cca.2026.121134_bb0090","article-title":"HER2-low breast Cancer: incidence, clinicopathologic features, and survival outcomes from real-world data of a large Nationwide cohort","volume":"36","author":"Baez-Navarro","year":"2023","journal-title":"Mod. Pathol."},{"issue":"71","key":"10.1016\/j.cca.2026.121134_bb0095","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cca.2026.121134_bb0100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4132\/jptm.2019.11.03","article-title":"HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation","volume":"54","author":"Ahn","year":"2020","journal-title":"J. Pathol. Transl. Med."},{"key":"10.1016\/j.cca.2026.121134_bb0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2022.08.031","article-title":"Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy","volume":"176","author":"Kang","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cca.2026.121134_bb0110","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231156669","article-title":"The association between HER2-low expression and prognosis of breast cancer: a systematic review and meta-analysis","volume":"15","author":"Tang","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.cca.2026.121134_bb0115","article-title":"Abstract P1-11-06: Multi-omics profiling of HER2-low breast cancer reveals clinically relevant subgroups and therapeutic pathways","volume":"83","author":"Chen","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2026.121134_bb0120","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.172366","article-title":"Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase-relevant subgroup with therapeutic prospects","volume":"8","author":"Chen","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.cca.2026.121134_bb0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/ijms22010173","article-title":"PI3K\/AKT\/mTOR Signaling pathway in breast Cancer: from molecular landscape to clinical aspects","volume":"22","author":"Miricescu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2026.121134_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16112009","article-title":"HER2-low luminal breast carcinoma is not a homogenous clinicopathological and molecular entity","volume":"16","author":"Andr\u00e9","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cca.2026.121134_bb0135","article-title":"Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis","volume":"375","author":"Conforti","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cca.2026.121134_bb0140","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2026.121134_bb0145","first-page":"1177","article-title":"Prognostic and biologic significance of ERBB2-low expression in early-stage breast Cancer","volume":"8","author":"Tarantino","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cca.2026.121134_bb0150","doi-asserted-by":"crossref","first-page":"993","DOI":"10.5858\/arpa.2023-0950-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast Cancer","volume":"147","author":"Wolff","year":"2023","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.cca.2026.121134_bb0155","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-023-01739-9","article-title":"High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients","volume":"25","author":"Nielsen","year":"2023","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.cca.2026.121134_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102538","article-title":"Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: a systematic review and meta-analysis","volume":"115","author":"Ergun","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cca.2026.121134_bb0165","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1038\/s41467-023-40715-x","article-title":"Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer","volume":"14","author":"Dai","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cca.2026.121134_bb0170","article-title":"Survival outcomes by tp53 mutation status in metastatic Breast Cancer","volume":"2018","author":"Meric-Bernstam","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cca.2026.121134_bb0175","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s12282-022-01364-y","article-title":"Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer","volume":"29","author":"Chen","year":"2022","journal-title":"Breast Cancer"},{"key":"10.1016\/j.cca.2026.121134_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021318","article-title":"Genomic alterations of Tumors in HER2-low Breast Cancers","volume":"25","author":"Tsai","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2026.121134_bb0185","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrclinonc.2013.124","article-title":"Luminal breast cancer: from biology to treatment","volume":"10","author":"Ignatiadis","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.121134_bb0190","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-Cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2026.121134_bb0195","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","article-title":"Annual Hazard rates of recurrence for breast Cancer during 24 years of follow-up: results from the international breast Cancer study group trials I to V","volume":"34","author":"Colleoni","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.121134_bb0200","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cca.2026.121134_bb0205","article-title":"Human epidermal growth factor receptor 2 testing in breast Cancer: ASCO-College of American pathologists guideline update","volume":"41","author":"Ac","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.121134_bb0210","article-title":"Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer","volume":"14","author":"Tarantino","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cca.2026.121134_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051413","article-title":"Discordance of HER2-low between primary Tumors and matched distant metastases in breast Cancer","volume":"15","author":"Almstedt","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cca.2026.121134_bb0220","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4143\/crt.2023.1138","article-title":"HER2-low breast Cancer: now and in the future","volume":"56","author":"Kang","year":"2024","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.cca.2026.121134_bb0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00428-023-03656-w","article-title":"Standardized pathology report for HER2 testing in compliance with 2023 ASCO\/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer","volume":"484","author":"Ivanova","year":"2024","journal-title":"Virchows Arch."},{"key":"10.1016\/j.cca.2026.121134_bb0230","doi-asserted-by":"crossref","DOI":"10.2174\/0118761429308361240823061634","article-title":"Recent advances in the glycolytic processes linked to tumor metastasis","volume":"17","author":"Qiong","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.cca.2026.121134_bb0235","doi-asserted-by":"crossref","DOI":"10.2174\/0118761429266116231123160809","article-title":"The regulatory mechanism of hypoxia-inducible factor 1 and its clinical significance","volume":"17","author":"Yin","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.cca.2026.121134_bb0240","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.21873\/anticanres.17344","article-title":"Exposure to hypoxic conditions up-regulates HER2 in breast Cancer cell lines","volume":"44","author":"Suganuma","year":"2024","journal-title":"Anticancer Res."},{"key":"10.1016\/j.cca.2026.121134_bb0245","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-16898-6","article-title":"HER2-low breast cancer shows a lower immune response compared to HER2-negative cases","volume":"12","author":"van den Ende","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2026.121134_bb0250","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-025-00867-z","article-title":"HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy","volume":"12","author":"Pizzamiglio","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.cca.2026.121134_bb0255","doi-asserted-by":"crossref","DOI":"10.2174\/0118761429310703240823045808","article-title":"Mechanism, potential, and concerns of immunotherapy for hepatocellular carcinoma and liver transplantation","volume":"17","author":"Sensi","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.cca.2026.121134_bb0260","article-title":"Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.cca.2026.121134_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104571","article-title":"Comprehensive characterization of HER2-low breast cancers: implications in prognosis and treatment","volume":"91","author":"Li","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cca.2026.121134_bb0270","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cca.2026.121134_bb0275","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/his.15213","article-title":"Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges","volume":"85","author":"Laokulrath","year":"2024","journal-title":"Histopathology"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126003165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126003165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:53:35Z","timestamp":1788900815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126003165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":55,"alternative-id":["S0009898126003165"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.121134","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological response and survival outcomes of HER2-low versus HER2-zero early breast Cancer: A systematic review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.121134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121134"}}